Antiviral Agents, Vaccines and Immunotherapies by Stephen K. Tyring

By Stephen K. Tyring

Not like the other resource at the topic, Antiviral brokers, Vaccines, and Immunotherapies analyzes the advantages and boundaries of each to be had drug, vaccine, and immunotherapy used in the prevention and regulate of viral ailments. This reference offers in-depth experiences of greater than 50 medicines and antiviral brokers for HIV, human herpesviruses, human papillomaviruses (HPV), influenza, respiration syncytial virus, hepatitis B, and analyzes their mechanisms of motion, dosage, unwanted side effects, and drug resistance. The booklet additionally presents an outline of using immunoglobulins and monoclonal antibodies for antiviral use and provides wide references, tables, and figures in the course of the textual content.

Show description

Read Online or Download Antiviral Agents, Vaccines and Immunotherapies PDF

Best metallurgy books

Wide-Gap Chalcopyrites

Chalcopyrites, specifically people with a large band hole, are interesting fabrics when it comes to their technological strength within the subsequent iteration of thin-film sunlight cells and when it comes to their uncomplicated fabric homes. They convey uniquely low disorder formation energies, resulting in strange doping and section habit and to super benign grain limitations.

Introduction to physical metallurgy

The most rules and purposes of the metallurgy are supplied during this e-book.

Additional info for Antiviral Agents, Vaccines and Immunotherapies

Sample text

Renal tubular dysfunction has occurred in at least one patient (72). Mucocutaneous responses. Occasional erythema, macules, and papules have been observed in patients taking d4T (65). Esophageal ulcers are also rarely seen. Lipoatrophy. Lipoatrophy is associated with mitochondrial toxicity, lactic acidemia, and insulin resistance. Switching from stavudine or zidovudine to abacavir can lead to modest increases in limb fat, but clinical lipoatrophy does not resolve (73–75). Neuromuscular weakness/respiratory failure.

Robbins, V. W. Snyder, and R. D’Aquila. 2003. ” N Engl J Med 349: 2304–2315. 14. De Clercq, E. 2002. New anti-HIV agents and targets. Med Res Reviews 22: 531–565. 15. Anonymous. 2003. ” MMWR 52: 1155–1157. 16. Enserink, M. 2003. ” Science 302: 1141–1142. Chapter 2 Antiretroviral Drugs to Treat Human Immunodeficiency Virus Infections INTRODUCTION In less than two decades, human immunodeficiency virus (HIV) has dramatically progressed from a little-known or understood infection to the cause of a major global epidemic.

Rebound of viral load levels during consistent treatment may indicate resistant HIV variants and may likely require changes in the current antiretroviral regimen. It should be noted that if one of the drugs in the antiretroviral regimen must be stopped, they all should be stopped and that a single-drug substitution can be made only if the patient’s viral load is completely suppressed. Antiretroviral Drugs to Treat Human Immunodeficiency Virus Infections 39 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Nucleoside analogs were the first line of defense for the treatment of HIV infection in 1987 (36).

Download PDF sample

Rated 4.03 of 5 – based on 45 votes